The Bioprocessing Summit
The Bioprocessing Summit

CONFERENCE SERIES: Bioprocessing & Manufacturing

Recorded at: Seventh Annual Bioprocessing Summit

Digital Course: Transient Protein Production in Mammalian Cells

 


Order Now

About this Product:

This digital course introduces both the fundamental concepts and technologies needed to establish transient protein production in mammalian cells. This allows for the rapid generation, purification and characterization of milligram-to-gram quantities of secreted or intracellular recombinant proteins for therapeutic, functional and structural studies. The course combines instruction and case studies in an interactive environment.

 

 



Product Details:
3 Presentations
116 Slides
Total Run Time: 2:32:43
Digital Download: $345.00
Single Copy: $345.00
Site License: $1380.00

Formats Available:
Digital Download
 
On Demand 
DVD

 
 

Agenda At A Glance:


Opening Remarks/Introductions

Richard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals


Fundamental Elements of Transient Protein Production

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.

  • Available transient expression systems
  • DNA vector elements for enhanced protein production

Fundamental Elements of Transient Protein Production

Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

  • HEK293 vs. CHO
  • The interplay of cells, medium, transfection reagent and supplements
  • Key considerations for maximizing yields

Implementing Transient Protein Production

Richard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals

  • What is your goal/objective for transient protein expression?
  • Case studies
  • Tools and strategies for evaluation of transiently expressed proteins

Speaker Biographies:


 Richard_AltmanRichard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals

Mr. Altman has over 23 years of experience working in the pharmaceutical industry. For the past two years, he has worked in the Molecular Sciences group at Alexion Pharmaceuticals developing antibody and non-antibody biologics. Prior to Alexion, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both high-throughput screening and protein therapeutic efforts. In addition, he has been involved in the generation of transgenic animal models and their characterization. Mr. Altman received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

 HenryChiouHenry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years he has worked as a principal scientist and now in product development and portfolio management for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.

 Dominic EspositoDominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on producing Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on mutant Ras genes including structural biology, biophysics and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.

About the Conference:

The Bioprocessing Summit brings together international leaders from over 30 countries to discuss today’s bioprocess issues, from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking, and features Small-Group Breakout Discussions, a vibrant poster display, a busy Exhibit Hall, and networking Receptions. Spanning five days, the 2015 meeting includes 12 Conference Programs, 8 Training Seminars and 10 Short Courses.

Who may be interested in this product (titles):

From pharmaceutical and biopharmaceutical companies, regulators and academic centers:

Head, Biopharmaceuticals
Head, Manufacturing, Molecular Biotechnology
VP of Manufacturing
Group Leader
Professor
Director, Biopharma
Business Director, Life Sciences
Principal Investigator
Principal Scientist
Senior Research Scientist
Senior Associate Scientist
Senior Scientist
Research Scientist
Scientist
Senior Research Associate
Research Associate, Pharmaceuticals
Postdoc
Researcher